NCRI research selected for presentation at ASCO 2020

Date published: May 19 2020

The NCRI Groups bring together clinicians, scientists, statisticians and lay representatives, amongst many others, to coordinate the development of a strategic portfolio of trials within their field. A number of studies developed by the NCRI Groups are being presented at the virtual ASCO Annual Meeting from 29-31 May 2020. More information on the studies, as well as links to the abstracts, can be found below.

NCRI Bladder and Renal Group

New standard in first-line therapy for advanced bladder cancer – JAVELIN

Thomas Powels, Chief Investigator on the JAVELIN Bladder 100 trial, is a member of the Advanced Bladder Cancer Subgroup of the NCRI Bladder and Renal Group. The Advanced Bladder Cancer Subgroup were involved in the development of this trial.

NCRI Children’s Group

Chemotherapy treatment for relapsed or refectory Ewing sarcoma – rEECur

The rEECur trial is part of the NCRI Children’s Group portfolio. The trial was discussed by the group and given full support. Martin McCabe, who is presenting the study, is Chair of the Biological Studies Subgroup of the NCRI TYA & Germ Cell Tumours Group.

Comparing drug and chemotherapy combinations and chemotherapy regimens for treating relapsed or refractory high-risk neuroblastoma – BEACON

The BEACON trial is part of the NCRI Children’s Group portfolio. The trial was discussed by the group and given full support.

NCRI Colorectal Group

Can blood tests predict the recurrence of bowel cancer earlier than CT scans – TRACC

The NCRI Colorectal Group reviewed the TRACC study and provided valuable advice regarding study design. Members of the group also supported the establishment of a network of centres to encourage recruitment to the study. Monica Jefford, a consumer member of the NCRI Colorectal Group, is a member of the trial management group.

Improving treatments for locally advanced rectal cancer to stop reoccurrence – ARISTOTLE

This trial was developed by the NCRI Colorectal Group. The trials Chief Investigator, Prof. David Sebag-Montefiore, was previously chair of the NCRI Colorectal Group and is the current chair of the NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad).

Comparing chemotherapy doses following bowel surgery – SCOT

The SCOT trial was supported by the NCRI Colorectal Group. Catherine Hanna, who is presenting a real-life implementation of the trial findings, is an early career researcher on the NCRI Colorectal Group and Anorectal Subgroup.

NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)

Reducing post-radiotherapy swallowing difficulties in patients with head and neck cancer

This trial was developed by NCRI CTRad who also provided support for radiotherapy quality assurance elements. The NCRI Head and Neck Group also supported the development of the original research idea and group members supported recruitment to the trial. Christopher Nutting, who is presenting the study, is a CTRad member and Chair of the Proton Beam Therapy Strategy Group.

NCRI Living With and Beyond Cancer (LWBC) Group

Using electronic self-reporting (eRAPID) to report treatment side effects

This study was developed by the previous NCRI Psychosocial Oncology and Survivorship Group which now forms part of the NCRI LWBC Group. Galina Velikova, who is presenting the study, is co-chair of the NCRI LWBC Group.

NCRI Lymphoma Group

Comparing treatments for follicular lymphoma, a type of low-grade non-Hodgkin lymphoma – Gallium

This trial had input from the NCRI Lymphoma Group and Low-Grade Lymphoma Subgroup. The trial is a successful partnership between the NCRI Lymphoma Group and the German Lymphoma Alliance Low-Grade Lymphoma Study Group.

NCRI Prostate Group

Treatment for men with metastatic prostate cancer that isn’t responding to hormone therapy – ProCAID

The ProCAID trial was discussed by the Advanced Disease Subgroup of the NCRI Prostate Group and the support of the group was included in the grant application. Simon Crabb, who is presenting the study, is a member of the NCRI Prostate and NCRI Bladder and Renal Groups.

Comparing alternative screening methods for prostate cancer – IP1-Prostagram

Members of the NCRI Prostate Group provided input into the design and set up phase of the IP1-Prostagram study. NCRI Consumer and member of the NCRI Prostate Group, Derek Price is a member of the clinical trial management group for IP1-Prostagram.

Comparing treatments for metastatic prostate cancer – IP2-ATLANTA

Members of the NCRI Prostate Group provided input into the design and set up phase of the IP2-ATLANTA study. NCRI Consumer and member of the NCRI Prostate Group, Derek Price is a member of the clinical trial management group for IP2-ATLANTA.

NCRI Sarcoma Group

Comparing chemotherapy regimens in Ewing sarcoma – EE2012

The EE2012 is one of the NCRI Sarcoma Group’s flagship trials. The trial was developed within the group and the group members also supported recruitment to the trial. Bernadette Brennan, who is presenting the study, is Chair of the NCRI Sarcoma Group.

Evaluating regorafenib in combination with vincristine/irinotecan in paediatric patients with rhabdomyosarcoma (RMS) and other solid tumours

A number of NCRI Sarcoma Group members are investigators on this trial.

Using cabazitaxel to treat advanced liposarcoma – EORTC-1202

The NCRI Sarcoma Group were involved in the development of the EORTC-1202 trial as well as actively recruiting trial participants.

Using cabazitaxel to treat metastatic gastrointestinal stromal tumour (GIST) – CaboGIST

The NCRI Sarcoma Group were involved in the development of the CaboGIST trial as well as actively recruiting trial participants.

NCRI Upper Gastrointestinal Group

Comparing immediate surgery with treatment before surgery for cancer of the pancreas – ESPAC-5F

The NCRI Upper Gastrointestinal Group Pancreas Subgroup was involved in the development of the ESPAC-5F trial. The trial was reviewed by CTRad at a proposals guidance meeting in 2012. Paula Ghaneh, who will be presenting the study, is a member of the Pancreatic Subgroup of the NCRI Upper Gastrointestinal Group.

Comparing gemcitabine alone with gemcitabine and capecitabine together after surgery to remove cancer of the pancreas – ESPAC-4

The Pancreatic Subgroup of the NCRI Upper Gastrointestinal Group supported the development of the ESPAC-4 trial.

Comparing surgical techniques to join the pancreas and bowel during surgery for pancreatic cancer – PANasta

The Pancreatic Subgroup of the NCRI Upper Gastrointestinal Group supported the development of the PANasta trial.